FDA rejects Intercept’s pitch for NASH as CEO fires back at the agency’s ‘evolving’ guidelines

Jason Mast

Editor

In a major setback for an already ailing field, the FDA has rejected obeticholic acid, the Intercept Pharmaceuticals compound that would have been the first …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA rejects Intercept’s pitch for NASH as CEO fires back at the agency’s ‘evolving’ guidelines

Jason Mast

Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Trump says he'll sign order on 'most-favored nation' drug price plans Monday

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

Revolution’s KRAS drugs appear competitive in several lung cancer settings

AstraZeneca reports Phase 3 win for Imfinzi; Roche to build new manufacturing site in China

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges

FDA re­jects In­ter­cept’s pitch for NASH as CEO fires back at the agency’s ‘evolv­ing’ guide­lines

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA rejects Intercept’s pitch for NASH as CEO fires back at the agency’s ‘evolving’ guidelines